Systemic Treatments for IBC

1. Systemic Treatments: IBC often begins with systemic treatments such as chemotherapy, targeted therapies, and sometimes immunotherapy. These treatments work throughout the entire body to shrink the tumor and target cancer cells that may have spread beyond the breast.
2. Surgery: After systemic treatment, surgery is usually the next step. The standard surgical procedure is a modified radical mastectomy with lymph node dissection, which removes the affected breast tissue and nearby lymph nodes to reduce the risk of recurrence. This type of surgery is typically done if the cancer has not spread to other parts of the body.
3. Radiation Therapy: Radiation therapy follows surgery to target any remaining cancer cells in the breast or chest wall, and may also include the regioal lymph nodes, further reducing the risk of local recurrence.

This aggressive, multi-faceted approach is necessary because IBC tends to spread quickly and may present without a palpable lump in the breast, making it harder to detect early. Understanding each treatment option, its role in managing IBC, potential side effects, and how to manage them can empower you to make informed decisions and feel more prepared for the journey ahead.

• Chemotherapy: Chemotherapy is usually the first line of treatment for IBC. When given before surgery, it is called “neoadjuvant chemotherapy”. The aim of neoadjuvant chemotherapy is to reduce the size of the tumor and eliminate cancer cells throughout the body. This helps make subsequent surgery and radiation more effective.
• Targeted Therapy: Targeted therapies are agents that specifically alter proteins and molecules on cancer cells. For example, for HER2-positive breast cancer, targeted therapies may include anti-HER2 drugs such as Trastuzumab and Pertuzumab.  Targeted therapies can be given in combination with chemotherapy agents.
• Hormonal Therapy: For IBC that is hormone receptor-positive, hormonal therapies may be used to block hormones that fuel cancer growth. These treatments help reduce the risk of recurrence after primary treatments are completed.
• Immunotherapy: Emerging options like immunotherapy are being explored in IBC to harness the body’s immune system to fight cancer cells. This can be particularly beneficial for patients whose cancers do not respond well to conventional treatments.

Why Systemic Treatments Are Essential: Due to IBC’s rapid progression and high likelihood of spreading to other parts of the body, systemic treatments are a cornerstone of its management. They work beyond the primary tumor site, offering a comprehensive approach to controlling the disease and improving outcomes.

Understanding your treatment plan and being aware of potential side effects allows you to better prepare for the journey ahead. We’ll guide you through each of these treatment options, including what to expect, managing side effects, and tips for coping during this challenging time.

Anthracycline and taxane-based chemotherapy are the mainstay treatments for IBC. These drugs are recommended by leading experts around the world. While the core drugs remain consistent, the specific chemotherapy schedules and dosage density may differ across treatment centres.

Anthracyclines

Anthracyclines, such as doxorubicin (Adriamycin) and epirubicin, are potent chemotherapy drugs commonly used as part of first-line treatment for IBC. They work by damaging the DNA within cancer cells, thereby preventing their ability to divide and grow.

• Mechanism: Anthracyclines intercalate into DNA and inhibit topoisomerase II activity, disrupting DNA replication and leading to cancer cell death.
• Application in IBC: Anthracyclines are effective in reducing tumor size and controlling the spread of cancer in IBC patients.
• Side Effects: Common side effects include nausea, hair loss, and increased susceptibility to infections.

Taxanes

Taxanes, such as paclitaxel (Taxol) and docetaxel (Taxotere), are another class of chemotherapy drugs used to treat IBC. They work by stabilizing microtubules within cancer cells, which are essential for cell division and growth.

• Mechanism: Taxanes interfere with microtubule function, leading to cell cycle arrest and ultimately, cell death.
• Application in IBC: Taxanes are effective in targeting rapidly dividing cancer cells, making them a valuable part of combination therapies for IBC.

Side Effects: Side effects may include neuropathy (nerve damage), joint and muscle pain, and fluid retention.

Hormone Therapy & CDK4/6 Inhibitors

For patients with hormone receptor-positive (HR+) IBC, hormone therapy (also referred to as endocrine therapy) is used to block estrogen, which fuels cancer growth. It is often combined with CDK4/6 inhibitors to improve effectiveness.

• Mechanism: Hormone therapy works by blocking estrogen receptors or lowering estrogen levels, preventing cancer cells from using estrogen to grow.
• Application in IBC: Hormone therapy is used in HR+ IBC cases to slow or stop cancer growth. It is often combined with CDK4/6 inhibitors for better effectiveness.
• Side Effects: Common side effects include hot flashes, joint pain, and bone thinning.

CDK4/6 inhibitors are used to slow down cancer cell growth by targeting proteins that regulate the cell cycle. These are typically combined with hormone therapy for HR+ IBC.

• Mechanism: CDK4/6 inhibitors block the proteins CDK4 and CDK6, which are essential for cancer cell division. This stops cancer cells from progressing through the cell cycle.
• Application in IBC: These inhibitors, such as abemaciclib (Verzenio), palbociclib (Ibrance), and ribociclib (Kisqali), may be used in the post-operative setting for selected IBC patients, as demonstrated by the MonarchE trial in high-risk HR+/HER2- breast cancer.
• Side Effects: Common side effects include low blood counts, fatigue, and diarrhea.

Targeted therapies focus on specific molecules involved in cancer growth and progression, offering more precise treatment options compared to traditional chemotherapy. There are currently limited studies on targeted therapies specifically for IBC. Given the high-risk nature of IBC, doctors often use information from studies on other high-risk breast cancers to guide treatment. For IBC, targeted therapies include:

HER2-Targeted Therapy (trastuzumab)

HER2-targeted therapies like trastuzumab (Herceptin) specifically target the HER2 protein found on the surface of some breast cancer cells. These therapies are crucial for HER2-positive IBC, improving outcomes and reducing the risk of recurrence.

• Mechanism: Trastuzumab binds to HER2 receptors, blocking signals that promote cancer cell growth and promoting immune system recognition and destruction of cancer cells.
• Application in IBC: Effective in HER2-positive IBC, targeted therapies like trastuzumab are integral to treatment plans, often used in combination with chemotherapy.
• Side Effects: Potential side effects include infusion reactions and cardiac toxicity.

Pertuzumab

Pertuzumab is a monoclonal antibody that targets and binds to HER2 receptors on cancer cells. It works by inhibiting dimerization (pairing) with other HER family receptors, particularly HER3, which interferes with signaling pathways that promote cancer cell growth and survival. Pertuzumab is often used in combination with trastuzumab and chemotherapy for HER2-positive breast cancers, including IBC.

• Mechanism: Pertuzumab inhibits HER2 dimerization with other HER family members, particularly HER3, blocking downstream signaling pathways that contribute to cancer cell proliferation.
• Application in IBC: Used in combination with trastuzumab and chemotherapy, pertuzumab enhances the effectiveness of HER2-targeted therapies in treating HER2-positive IBC.
• Side Effects: Common side effects include infusion reactions, diarrhea, and potential cardiac dysfunction.

• For patients with HER2+ IBC:

• Who achieved a pCR: Adjuvant pertuzumab (Perjeta) and trastuzumab (Herceptin) are recommended if the cancer responds well to treatment.
• HER2+ IBC patients who did NOT achieve a pCR: If the cancer does not respond well, then T-DM1 (trastuzumab emtansine) may be considered.

Recent advancements have introduced new avenues for treating IBC, including immunotherapy and PARP inhibitors. These therapies offer promising alternatives or complements to traditional approaches, particularly in targeted patient populations.

Immunotherapy

While not yet fully established in IBC treatment protocols, recent research on non-IBC breast cancer has shown promising results with immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab), producing high response rates. Though not yet specific to IBC, these findings suggest a potential future role for immunotherapy in treating IBC.

Research is ongoing to explore its efficacy in harnessing the immune system to fight cancer, including IBC.

• Mechanism: Immunotherapy works by enhancing the body’s immune response against cancer cells, using agents like immune checkpoint inhibitors or CAR-T cell therapy.
• Application in IBC: Exploring efficacy and safety in clinical trials. Hopeful future treatment option.
• Side Effects: Potential side effects include immune-related adverse events, such as inflammation of organs like the lungs, liver, and intestines.

PARP Inhibitors

PARP inhibitors, such as olaparib (Lynparza), are targeted therapies used in the treatment of certain types of breast cancer, including IBC. They exploit vulnerabilities in cancer cells that have defects in DNA repair mechanisms, such as those caused by mutations in BRCA1 and BRCA2 genes.

• Mechanism: PARP inhibitors block PARP enzymes, preventing cancer cells from repairing DNA damage and leading to their death.
• Application in IBC: PARP inhibitors are particularly beneficial for patients with BRCA mutations, offering a targeted approach to treatment.
• Side Effects: Common side effects include nausea, fatigue, and potential risks of bone marrow suppression.

Understanding the mechanisms and applications of these systemic treatments is crucial for managing IBC effectively. By targeting cancer cells throughout the body, these therapies aim to control the disease, improve outcomes, and enhance the quality of life for patients with IBC.

Current Challenges:

• IBC’s Nature: IBC frequently spreads to distant parts of the body and has a generally poor prognosis, underscoring the need for new and more effective treatments.
• High-Dose Chemotherapy: High-dose chemotherapy with autologous hematopoietic stem cell transplantation (AHSCT) has been found to be too toxic without clear benefits.
• Standard Treatments: Currently, only anti-HER2 therapies (pertuzumab, trastuzumab, T-DM1) are integrated into the standard treatment protocol for IBC.

Future Directions:

• Need for New Approaches: There is an urgent need for new treatment strategies, especially those tailored specifically for IBC.
• Global Collaboration: Utilizing a global, multicenter approach for IBC-specific clinical trials can enhance the success of these trials, leading to improved treatment outcomes for IBC patients.

Source: Update on systemic treatment for newly diagnosed inflammatory breast cancer – PMC 

• Initial Consultation: Before starting chemotherapy, you’ll meet with your oncologist to discuss your specific treatment plan. IBC is typically treated with a combination of drugs known as a “chemotherapy regimen,” which often includes anthracyclines and taxanes. These drugs are designed to target aggressive cancer cells and shrink tumors before surgery. Your oncologist will explain the treatment schedule, potential side effects, and what to expect during your sessions, which may be more intense given the aggressive nature of IBC.
• Port Placement: Due to the need for frequent and intensive treatments, many IBC patients will have a port (a small device implanted under the skin) placed in their chest. This port makes it easier to administer chemotherapy and draw blood, reducing the need for repeated needle sticks. The procedure is typically quick and done on an outpatient basis, with a short recovery time.
• Treatment Sessions: Chemotherapy sessions for IBC can last several hours, depending on the specific drugs being administered. Treatments are often given in cycles, with rest periods in between to allow your body to recover. Bring items like a book, headphones, or a tablet to help pass the time. Given the intensity of IBC treatment, it’s important to keep yourself mentally and physically comfortable during these long sessions.
• Side Effects: Common side effects of chemotherapy for IBC include fatigue, nausea, hair loss, changes in taste, and increased susceptibility to infections. Due to the high-dose nature of IBC chemotherapy, side effects can be more pronounced. Your medical team will provide medications and tips to help manage these symptoms and support your overall well-being during treatment.

• Comfort is Key: Wear comfortable clothing to your sessions, and bring a cozy blanket or pillow. Some clinics can be chilly, and comfort can make a significant difference during long treatments.
• Stay Hydrated: Drinking plenty of water before and after chemotherapy can help with managing side effects like nausea and support your overall recovery. Staying hydrated is particularly important for IBC patients due to the aggressive treatment regimen. Your care team may recommend home hydration if necessary.
• Gentle Nutrition: Eat small, frequent meals that are easy on the stomach. Foods like ginger tea and crackers can help combat nausea. Because IBC treatment can be intense, focus on nutrient-rich foods that provide energy and are gentle on your digestive system.
• Create a Support System: Having a friend or family member accompany you to chemo sessions can provide emotional support and help you feel more at ease. For IBC patients, having someone who understands the intensity of your treatment can be incredibly comforting.
• Prepare Your Home: Before starting chemotherapy, stock up on easy-to-prepare meals, and create a cozy rest area where you can relax and recover after treatment. IBC chemotherapy can be physically demanding, so having a comfortable space ready can make a big difference.

• Consultation: You’ll meet with your surgeon orl oncologist to discuss the specifics of your surgery. For IBC, a modified radical mastectomy (MRM) is typically recommended. This involves removing the entire breast, including the skin, nipple, areola, and most of the axillary (underarm) lymph nodes. The aim is to remove as much of the cancer as possible to improve treatment outcomes.
• Lymph Node Removal: During the MRM, the surgeon will also remove lymph nodes from the underarm area. This is an important step in staging the cancer and planning further treatment.
• Skin-Sparing and Reconstruction: Immediate reconstruction is generally not advised for IBC due to the aggressive nature of the disease and the necessity of post-surgery radiation. Reconstruction is usually considered after completing all treatments, once the chest area has had time to heal.
• Consideration of Bilateral Mastectomy: While it’s understandable to want to take every possible measure, surgeons typically prefer not to perform a prophylactic bilateral mastectomy (removal of both breasts) unless medically necessary. This approach is due to the increased risk of complications, such as infection, and the potential for treatment delays that could impact overall outcomes. Your surgical team will discuss the best approach for your individual case.
• Drain Care: After surgery, you’ll likely have surgical drains in place to help remove excess fluid and prevent complications like fluid build-up (seromas). These drains are usually kept in place for one to two weeks.
• Physiotherapy: Physiotherapy plays a key role in recovery, helping you regain mobility in the shoulder and arm on the side of the surgery. It also helps reduce the risk of lymphedema, which is swelling caused by the build-up of lymph fluid.

• Prepare for Drains: Bring button-up shirts to the hospital that can easily accommodate surgical drains. Many patients find drain belts or pouches helpful for managing drains discreetly and comfortably.
• Post-Surgery Care: Arrange for someone to help you at home during the first week or two after surgery. This assistance can make it easier to manage daily activities, especially if you experience limited mobility.
• Pain Management: Discuss pain management options with your healthcare team before surgery. Managing pain effectively can make your recovery smoother.
• Arm Exercises: Start gentle arm exercises as soon as your surgeon gives the go ahead. This can help with your range of motion and prevent complications like stiffness or frozen shoulder.
• Emotional Support: Undergoing surgery for IBC can be an emotional journey. Connecting with others who’ve had similar experiences through support groups or online communities can provide valuable insights and comfort.

For more detailed information, you can visit the Sunnybrook Health Sciences Centre’s guide on mastectomy here.

• Consultation and Planning: Before starting radiation, you’ll have a detailed planning session with your radiation oncologist. Given the aggressive nature of IBC, radiation is typically more intensive and targeted. During this session, your treatment area will be precisely mapped out, often covering the chest wall, underarm (axilla), and possibly the collarbone area. The radiation oncologist will determine the appropriate radiation dose, measured in grays (Gy), and the number of sessions based on several IBC-specific factors, including:
• Extent of Skin Involvement: IBC often affects the skin and underlying lymphatic vessels. This may necessitate a higher dose of radiation or a larger treatment area to ensure all affected tissue is thoroughly treated.
• Use of a Bolus: For IBC patients, a bolus—a material that mimics tissue—is often applied to the skin during radiation treatments. The bolus ensures that the radiation dose is concentrated at the skin’s surface, which is crucial for IBC patients, as the disease frequently involves the skin. This technique helps to target cancer cells more effectively and reduce the risk of recurrence in the skin.
• Radiation Boost: In addition to standard radiation therapy, an IBC patient might receive a “boost” of radiation. This boost involves delivering an extra dose of radiation directly to the area where the tumor was most active or where residual cancer cells might be present. The boost is typically administered towards the end of the treatment course and is designed to further decrease the risk of local recurrence.
• Response to Neoadjuvant Therapy: The effectiveness of chemotherapy prior to surgery can influence the radiation plan. If the cancer has responded well, the dosage might be adjusted accordingly. Conversely, if there are residual cancer cells, a more aggressive approach may be needed.
• Surgical Margins: For IBC, ensuring clean surgical margins is crucial. If the cancer was close to the edges of the tissue removed, your oncologist might recommend a higher radiation dose or additional sessions to lower the risk of recurrence.
• Type of Radiation Therapy: IBC patients often receive external beam radiation, but the specific technique (such as intensity-modulated radiation therapy, or IMRT) may vary based on the extent of the disease and the areas being treated.
• Concurrent Treatments: Radiation for IBC is often coordinated with other treatments like continued systemic therapy. The dosage and schedule will be designed to complement these treatments without overwhelming your body.
• Treatment Sessions: Radiation treatments for IBC are typically quick, lasting only a few minutes per session, but they occur daily over several weeks, often spanning five to six weeks. While the procedure itself is painless, it’s crucial to remain still during each session to ensure that the radiation precisely targets the cancer-affected areas.
• Skin Care: The skin in the treated area may become red, dry, or irritated over time, which is a common side effect, particularly with IBC due to the higher doses often used and the application of a bolus. Your healthcare team will provide detailed guidance on how to care for your skin during treatment. Following these recommendations is essential to minimize discomfort and protect your skin.

• Creams and Lotions: Use gentle, unscented lotions to keep the skin moisturized. Ask your medical team for specific product recommendations that are safe to use during radiation. Many IBC patients find relief with aloe vera gel or creams formulated specifically for radiation burns.
• Loose Clothing: Wear soft, loose clothing to minimize irritation to the treated area. Avoid tight or rough fabrics that could rub against the sensitive skin. For IBC patients, this is particularly important as the treatment area may be extensive.
• Hydration: Staying well-hydrated is essential during radiation therapy, especially for IBC patients who might be undergoing more intensive treatment. Drink plenty of water to support your body’s recovery and maintain healthy skin.
• Rest and Nutrition: Radiation can cause fatigue, particularly in IBC patients due to the intensity of the treatment. Prioritize rest and ensure you’re eating a balanced diet rich in nutrients to help your body heal and maintain strength.
• Support: Connecting with others who’ve been through radiation for IBC can provide invaluable emotional support and practical tips. Consider joining a support group where you can share experiences and gain insights specific to IBC.

For IBC patients whose cancer cells overexpress the HER2 protein, targeted therapies like trastuzumab (Herceptin) and pertuzumab (Perjeta) are commonly used. These drugs are monoclonal antibodies that specifically target the HER2 protein on cancer cells, helping to slow or stop the growth of the tumor.

In Canada, trastuzumab is widely available for HER2-positive IBC patients, but access to pertuzumab may vary based on the stage of cancer and provincial guidelines. For example, pertuzumab is generally recommended for use in combination with trastuzumab and chemotherapy, particularly for HER2-positive cases with a higher risk of recurrence. However, the availability of pertuzumab and its coverage may differ depending on the province and specific patient circumstances. It is important to discuss with your oncologist about the best treatment options available and how they are covered by provincial health plans.

Another advanced therapy for HER2-positive IBC is ado-trastuzumab emtansine (Kadcyla), an antibody-drug conjugate that delivers chemotherapy directly to HER2-positive cancer cells, minimizing damage to surrounding healthy tissue. This therapy may be used if there are residual cancer cells after initial treatments.

For patients with IBC who are HER2-negative but have other specific genetic mutations, targeted therapies like PARP inhibitors (e.g., olaparib) may be considered. These drugs are particularly useful for patients with BRCA1 or BRCA2 gene mutations and work by preventing cancer cells from repairing their DNA, leading to cell death.

Clinical Trials: Due to the aggressive nature of IBC, participation in clinical trials for new targeted therapies may be recommended. Canada is home to several world-class cancer research centers, such as the Princess Margaret Cancer Centre in Toronto, which often run clinical trials for innovative IBC treatments. Your oncologist can help you explore available trials that may be appropriate for your situation.

• Monitoring: Regular monitoring through imaging and blood tests is essential during targeted therapy to assess how well the treatment is working and manage any side effects.
• Side Effects: Common side effects of targeted therapies can include heart issues, diarrhea, and fatigue. It’s important to discuss any side effects with your healthcare team, as they can provide supportive care and make adjustments to your treatment plan if necessary.
• Support: Joining an IBC-specific support group can be invaluable when undergoing targeted therapies. Other patients can share their experiences and offer advice on managing side effects and navigating the treatment process.

• Tamoxifen: Tamoxifen is often prescribed for premenopausal women with HR+ IBC. It works by blocking estrogen receptors on cancer cells, preventing the hormone from binding and fueling the cancer’s growth. Tamoxifen is typically taken for 5 to 10 years after initial treatment, depending on your specific situation.
• Aromatase Inhibitors (AIs): For postmenopausal women, aromatase inhibitors such as anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin) are commonly used. These drugs lower estrogen levels by blocking the enzyme aromatase, which is responsible for converting androgens into estrogen in the body. AIs are often prescribed for several years following surgery, chemotherapy, or radiation.
• Ovarian Suppression: In premenopausal women, ovarian suppression may be recommended alongside tamoxifen or AIs. This can be achieved through medication such as goserelin (Zoladex) or through surgery to remove the ovaries (oophorectomy). This treatment reduces the amount of estrogen produced by the ovaries, making hormonal therapy more effective.

• Adherence: Hormonal therapy is typically a long-term treatment, and adherence is crucial for reducing the risk of recurrence. It’s important to take your medication as prescribed, even if you feel well.
• Managing Side Effects: Common side effects of hormonal therapy include hot flashes, joint pain, and bone thinning. Your healthcare team can offer strategies to manage these side effects, such as medications, lifestyle changes, or complementary therapies.
• Bone Health: Aromatase inhibitors can increase the risk of osteoporosis, so it’s important to monitor bone density and take steps to protect your bone health. Calcium and vitamin D supplements, along with weight-bearing exercises, can be beneficial.
• Emotional Support: Hormonal therapy can sometimes affect your mood or emotional well-being. Joining a support group or talking to a counselor who specializes in cancer care can provide much-needed support during this time.

• Focus on Nutrient-Rich Foods: Incorporate plenty of fruits, vegetables, whole grains, and lean proteins into your diet. Foods rich in antioxidants, like berries and leafy greens, and anti-inflammatory foods, such as fatty fish and nuts, are particularly beneficial.
• Boost Your Immune System: Include foods high in vitamin C, like oranges and strawberries, and zinc-rich options, such as nuts and seeds.
• Stay Energized: Choose complex carbohydrates like oats and quinoa to keep your energy levels steady.

Resources: Check out the Canadian Cancer Society’s nutrition guidelines for cancer patients.

• Engage in Gentle Activities: Try walking, swimming, or yoga, which are gentle on your joints and can be adapted to your energy levels.
• Reap the Benefits: Regular exercise can improve your mood, help you sleep better, and enhance your physical function. Explore gentle exercise routines from the Canadian Cancer Society.
• Resources: Download our Gentle Exercise Guide for IBC Patients and use an exercise log to track your progress and set goals.

• Practice Mindfulness: Incorporate deep breathing exercises, meditation, and progressive muscle relaxation into your routine. You can try meditation apps like Headspace , Calm or Insight Timer.
• Enjoy Your Hobbies: Engage in activities that bring you joy, spend time in nature, or connect with loved ones to help reduce stress.
• Build a Support Network: Surround yourself with a strong support system, whether through friends, family, or IBC-specific support groups.
• Resources: Download our guide on mindfulness practices for stress management. Coming Soon!

Call to Action: Use our downloadable guides and checklists to help you integrate these lifestyle changes into your daily routine.